|
51 |
Are real world data real world data?
Enthalten in Leukemia Bd. 39, 11.9.2025, Nr. 10, date:10.2025: 2311-2312
|
|
|
|
52 |
Can Immune Therapy Cure Acute Myeloid Leukemia?
Enthalten in Current treatment options in oncology Bd. 24, 22.3.2023, Nr. 5, date:5.2023: 381-386
|
|
|
|
53 |
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Enthalten in Blood cancer journal Bd. 13, 5.9.2023, Nr. 1, date:12.2023: 1-4
|
|
|
|
54 |
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia
Enthalten in Leukemia Bd. 39, 25.2.2025, Nr. 4, date:4.2025: 810-815
|
|
|
|
55 |
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia
Enthalten in Leukemia Bd. 38, 1.6.2024, Nr. 7, date:7.2024: 1469-1473
|
|
|
|
56 |
Changing causes of death in persons with haematological cancers 1975–2016
Enthalten in Leukemia Bd. 36, 16.5.2022, Nr. 7, date:7.2022: 1850-1860
|
|
|
|
57 |
Chronic lymphocytic leukemia in 2020: a surfeit of riches?
Enthalten in Leukemia Bd. 34, 11.5.2020, Nr. 8, date:8.2020: 1979-1983
|
|
|
|
58 |
Clinical trials: design, endpoints and interpretation of outcomes
Enthalten in Bone marrow transplantation Bd. 57, 7.1.2022, Nr. 3, date:3.2022: 338-342
|
|
|
|
59 |
Commentary on the 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms
Enthalten in Leukemia Bd. 39, 21.3.2025, Nr. 4, date:4.2025: 1009-1010
|
|
|
|
60 |
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
Enthalten in Leukemia Bd. 36, 12.10.2022, Nr. 12, date:12.2022: 2875-2882
|
|
Administration
